MedStar Authors catalog › Details for: Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Citation: Diabetes, Obesity & Metabolism. , 2017 Apr 06.Journal: Diabetes, obesity & metabolism.Published: 2017ISSN: 1462-8902.Full author list: Wysham C; Bonadonna RC; Aroda VR; Puig-Domingo M; Kapitza C; Stager W; Yu C; Niemoeller E; Souhami E; Bergenstal RM; LixiLan-L trial investigators.UI/PMID: 28386990.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.1111/dom.12961 (Click here)Abbreviated citation: Diabetes Obes Metab. , 2017 Apr 06.Abstract: AIM: To assess the impact of baseline characteristics on clinical outcomes in the LixiLan-L trial, a randomized open-label trial designed to evaluate the efficacy and safety of iGlarLixi, a novel fixed-ratio combination of insulin glargine 100 U (iGlar) plus lixisenatide, in comparison with iGlar over 30 weeks in a population of patients with type 2 diabetes mellitus (T2DM) inadequately controlled on a previous regimen of basal insulin alone or in combination with one or two oral glucose-lowering drugs.Abstract: METHODS: In this exploratory analysis of LixiLan-L (N=736), efficacy outcomes were assessed within population subgroups derived from the following baseline characteristics: glycated haemoglobin (HbA1c; <8, >8% [<64, >64mmol/mol]); duration of T2DM (<10, >10years); body mass index (<30, >30kg/m<sup>2</sup> ). Furthermore, the incidence of symptomatic hypoglycaemia with plasma glucose <3.9mmol/L (<70mg/dL) was also analysed according to the same subgroups.Abstract: RESULTS: Compared with the iGlar treatment group, patients treated with iGlarLixi showed consistently greater reductions in HbA1c during the treatment period, with higher percentages of patients achieving the HbA1c target level of <7% (53mmol/mol) in all of the subpopulations tested (p<0.0001 for all), having consistent mitigation of body weight gain and with no major differences in the incidence of hypoglycaemia.Abstract: CONCLUSIONS: iGlarLixi consistently improved glycaemic control compared with iGlar in all baseline characteristic subgroups of patients with T2DM inadequately controlled with insulin, including difficult-to-treat subgroups of patients with long duration of diabetes, obesity and high HbA1c.Abstract: Copyright This article is protected by copyright. All rights reserved.
